Lead Product(s) : Remifentanil
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Al-Azhar University
Deal Size : Inapplicable
Deal Type : Inapplicable
Remifentanil and Remimazolam to Limit Patient Movement
Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 04, 2024
Lead Product(s) : Remifentanil
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Al-Azhar University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remifentanil
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Yichang Humanwell Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation
Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Critical Illness.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2015
Lead Product(s) : Remifentanil
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Yichang Humanwell Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remifentanil
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 11, 2015
Lead Product(s) : Remifentanil
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remifentanil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
Remifentanil and Glycemic Response in Cardiac Surgery
Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 28, 2015
Lead Product(s) : Remifentanil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remifentanil
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anesthesia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 28, 2013
Lead Product(s) : Remifentanil
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remifentanil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tachycardia, Ventricular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 17, 2013
Lead Product(s) : Remifentanil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remifentanil
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Validation of Medasense Pain Response Index (PRI)
Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of General Surgery.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2013
Lead Product(s) : Remifentanil
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remifentanil
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Remifentanil Only vs. Midazolam and Meperidine During Elective Colonoscopy
Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 26, 2012
Lead Product(s) : Remifentanil
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remifentanil
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Remifentanil Versus Paracetamol for Pain Treatment External Cephalic Versions.
Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pregnancy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 13, 2010
Lead Product(s) : Remifentanil
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
